These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17598653)

  • 21. [Complete remission of minimal change nephrotic syndrome with type 2 diabetes mellitus treated by microemulsion formulation of cyclosporin and fluvastatin].
    Makibayashi K; Fukatsu A; Kita T
    Nihon Jinzo Gakkai Shi; 2002 Mar; 44(2):109-13. PubMed ID: 11974950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
    Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
    Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study.
    Hongo M; Tsutsui H; Mawatari E; Hidaka H; Kumazaki S; Yazaki Y; Takahashi M; Kinoshita O; Ikeda U
    Circ J; 2008 May; 72(5):722-8. PubMed ID: 18441450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism.
    Wittke R
    Sports Med; 1999 May; 27(5):329-35. PubMed ID: 10368879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
    Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
    Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.
    Winkler K; Abletshauser C; Hoffmann MM; Friedrich I; Baumstark MW; Wieland H; März W
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5485-90. PubMed ID: 12466341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
    Widimský J; Hulínský V; Balazovjech I; Lánská V
    Vnitr Lek; 1999 Apr; 45(4):210-6. PubMed ID: 11045181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes.
    Winkler K; Abletshauser C; Friedrich I; Hoffmann MM; Wieland H; März W
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1153-9. PubMed ID: 15001601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of creatine kinase elevation during treatment with fluvastatin.
    Benghozi R; Bortolini M; Jia Y; Isaacsohn JL; Troendle AJ; Gonasun L
    Am J Cardiol; 2002 Jan; 89(2):231-3. PubMed ID: 11792351
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus.
    Jokubaitis LA; Knopp RH; Frohlich J
    J Intern Med Suppl; 1994; 736():103-7. PubMed ID: 7986302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients.
    Holdaas H; Hagen E; Asberg A; Lund K; Hartman A; Vaidyanathan S; Prasad P; He YL; Yeh CM; Bigler H; Rouilly M; Denouel J
    Int J Clin Pharmacol Ther; 2006 Apr; 44(4):163-71. PubMed ID: 16625985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of combined prednisone + fluvastatin on cholesterol and bilirubin in pediatric patients with minimal change nephropathy.
    Song M; Li A; Gong J; Yang D; Ma L; Zhou X; Yan Y; Xie Y
    Clin Ther; 2013 Mar; 35(3):286-93. PubMed ID: 23485078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different galenic formulations of fluvastatin have equal lipid-lowering potential but differ in reducing lipemia-induced endothelial dysfunction.
    Westphal S; Abletshauser C; Luley C
    Coron Artery Dis; 2009 Jan; 20(1):81-5. PubMed ID: 19060628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on lipid peroxidation].
    Kowalski J; Pawlicki L; Grycewicz J; Błaszczyk J; Irzmański R; Cegliński T; Kowalczyk E; Liban-Gałka B
    Wiad Lek; 2005; 58(7-8):386-90. PubMed ID: 16425789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Iron Overload on the Activity of Na,K-ATPase and Lipid Profile of the Human Erythrocyte Membrane.
    Sousa L; Garcia IJ; Costa TG; Silva LN; Renó CO; Oliveira ES; Tilelli CQ; Santos LL; Cortes VF; Santos HL; Barbosa LA
    PLoS One; 2015; 10(7):e0132852. PubMed ID: 26197432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes].
    Sarano NE; Kozlov SG; Tvorogova MG; Liakishev AA; Naumov VG
    Kardiologiia; 2003; 43(4):30-5. PubMed ID: 12891248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.